Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. is a Cayman Islands blank check company formed to complete a merger, share exchange, asset acquisition, recapitalization, or similar business combination. It raised capital through an IPO and private placement and is currently searching for a target, with a stated focus on the pharmaceutical industry.

0.09

0.09

— Drugs Made In America Acquisition II Corp.
%
Blank check acquisition vehicle100% Capital raised to acquire an operating company through a future business combination.

The company does not sell products or services to end customers today; its counterparties are investors, the sponsor,...

  • Public equity investorsprimary

    Buy IPO units and rights for exposure to a future acquisition and potential redemption value.

  • Sponsor and placement investorsprimary

    Provide private placement capital and support the transaction structure and search process.

  • Target company ownersprimary

    Would exchange their business for public-company access, capital, and liquidity in a merger.

  • Pharmaceutical acquisition targetsemerging

    Potential operating businesses in the pharma sector that fit the company's stated search mandate.

The company is incorporated in the Cayman Islands but is managed from the United States and listed in the U.S...

  • •Cayman Islands incorporation
  • •United States management and capital markets access
  • •U.S. IPO and public shareholder base
  • •Future operating geography depends on acquisition target
  • •Pharmaceutical search focus may broaden cross-border exposure

The company’s near-term strategy is to identify and complete an initial business combination, using IPO proceeds,...

01
Identify a suitable pharmaceutical targetshort-term

The company has no operating business yet, so deal sourcing is the core value-creation task.

02
Close an initial business combinationshort-term

Completion of a transaction converts the SPAC from a cash shell into an operating company.

03
Maintain shareholder support and redemption flexibilityshort-term

Investor redemptions can reduce cash available for the deal and affect closing certainty.

The company is pre-revenue and depends on successfully finding and closing a business combination, so execution risk is...

critical

Failure to complete an initial business combination

The company exists to acquire a business; without a deal, it cannot transition into operations.

Scope
All current capital and the SPAC structure
Materiality
high
high

Shareholder redemptions

Investors may redeem shares before closing, reducing the cash available to fund the transaction.

Scope
Trust account funding and deal financing
Materiality
high
high

Target selection and diligence risk

A weak or overvalued acquisition can destroy value after closing.

Scope
Pharmaceutical target screening
Materiality
high
medium

Public-company compliance and transaction costs

Legal, accounting, and due diligence expenses continue while the company searches for a target.

Scope
Pre-combination overhead
Materiality
medium
Trust account interest income
Offsets general and administrative expenses and reduces reported net loss
Deferred underwriting fee
Creates a contingent transaction cost tied to deal success
Offering costs and public-company expenses
Drive pre-combination losses and reduce net assets
Equity classification of units and rights
Affects balance sheet presentation and dilution analysis

Drugs Made In America Acquisition Corp.

DMAA · Blank Checks

AA Mission Acquisition Corp. II

YCY · Blank Checks

FACT II Acquisition Corp.

FACT · Aircraft Parts & Auxiliary Equipment, NEC

FutureTech II Acquisition Corp.

Biological Products, (No Diagnostic Substances)

Sizzle Acquisition Corp. II

SZZL · Blank Checks

RF Acquisition Corp II

RFAI · Blank Checks

: 28.4.2026